Drug Profile
Research programme: anticancer fusion protein - Pivotal Biosciences
Alternative Names: LEC/mab fusion protein; LEC/monoclonal antibody fusion protein; PB 103; PB3Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Southern California
- Class Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 15 Jun 2010 Preclinical development is ongoing in USA
- 04 Jun 2004 Preclinical trials in Cancer in USA (unspecified route)